Experience with cyclosporine in endogenous uveitis posterior

D A Hesselink, G S Baarsma, R W A M Kuijpers, P M van Hagen

Research output: Contribution to journalReview articlepeer-review


Treatment with cyclosporine (CsA) has considerably improved the visual prognosis of patients suffering from endogenous posterior uveitis (EPU). However, the therapeutic benefits of CsA are partially outweighed by its many side effects, most notably nephrotoxicity and hypertension. Low-dose CsA regimens have reduced toxicity but have not been able to completely eliminate this problem. New therapeutic approaches, such as anti-tumor necrosis factor alpha treatment or immunosuppression with drugs including tacrolimus, sirolimus, and interleukin-2 receptor antibodies, are currently under evaluation. Hopefully such strategies will further reduce the morbidity of EPU and minimize the adverse effects associated with conventional therapies.

Original languageEnglish
Pages (from-to)372S-377S
JournalTransplantation Proceedings
Issue number2 Suppl
Publication statusPublished - Mar 2004


  • Cyclosporine/adverse effects
  • Drug Interactions
  • Humans
  • Hypertension/chemically induced
  • Immunosuppressive Agents/therapeutic use
  • Kidney/drug effects
  • Uveitis, Posterior/drug therapy


Dive into the research topics of 'Experience with cyclosporine in endogenous uveitis posterior'. Together they form a unique fingerprint.

Cite this